Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Immune-Suppressed, Not Immune-Cold: HMOX1-CD14-Immunoproteasome Axis and Structure-Guided Combination Pharmacotherapies in Isocitrate Dehydrogenase-Mutant Glioblastoma.

Omics : a journal of integrative biology - 1 Jan 2026

Gürkan Şali Sezin, Özkaya Şeyma Çolakoğlu, Budak Betül, Güllüoğlu Şükrü, Nacar Cevdet, Bayrak Ömer Faruk, Arga Kazım Yalçın, Güney Ahmet İlter

Abstract excerpt

Glioblastoma (GBM) remains one of the most aggressive human malignancies, and its biological diversity is largely shaped by the isocitrate dehydrogenase (IDH) mutation status. Although apoptosis, autophagy, and ferroptosis have each been implicated in GBM pathophysiology, their coordinated regulation through the immunoproteasome (i-PSM) axis has not been systematically explored. Here, we integrated transcriptomic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to Gene Expression Regulation, Neoplastic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glioblastoma

Share to Heme Oxygenase-1

Share to Isocitrate Dehydrogenase

Share to Lipopolysaccharide Receptors

Share to Mutation

Share to Proteasome Endopeptidase Complex

Source

Identifiers

PMID: 41468107
DOI: 10.1177/15578100251408286

Genes

CD14
HMOX1
BAK1
CTSB
CTSS
CYBB
FTH1
PRKCD
RRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Immune-Suppressed, Not Immune-Cold: HMOX1-CD14-Immunoproteasome Axis and Structure-Guided Combination Pharmacotherapies in Isocitrate Dehydrogenase-Mutant Glioblastoma.PMID 41468107Read ↗

Single-Cell Transcriptomics Reveals the Heterogeneity of the Immune Landscape of IDH-Wild-Type High-Grade Gliomas.Semantic proximity Read ↗

Immune landscape of isocitrate dehydrogenase stratified human gliomasSemantic proximity Read ↗

Immune landscape of isocitrate dehydrogenase-stratified primary and recurrent human gliomas.Semantic proximity Read ↗

Perspectives of immunotherapy in isocitrate dehydrogenase-mutant gliomas.Semantic proximity Read ↗

Integrated analysis implicates novel insights of NMB into lactate metabolism and immune response prediction in primary glioblastomaSemantic proximity Read ↗

Integrated pharmaco-proteogenomics defines two subgroups in isocitrate dehydrogenase wild-type glioblastoma with prognostic and therapeutic opportunities.Semantic proximity Read ↗

Single-cell profiling of peripheral and local immune compartments reveal unique genotype-independent prognostic immune signatures across isocitrate dehydrogenase-stratified glioma.Semantic proximity Read ↗

A specific immune signature for predicting the prognosis of glioma patients with IDH1-mutation and guiding immune checkpoint blockade therapy.Semantic proximity Read ↗

Differential microglia and macrophage profiles in human IDH-mutant and -wild type glioblastomaSemantic proximity Read ↗

Protocol for AI-powered classification of IDH-mutant astrocytoma using GUIDE.Semantic proximity Read ↗

Novel macrophage-related gene prognostic index for glioblastoma associated with M2 macrophages and T cell dysfunctionSemantic proximity Read ↗

Proteogenomics of glioblastoma associates molecular patterns with survivalSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.